Recent progress in development of siRNA delivery vehicles for cancer therapy

Hyun Jin Kim; Ahram Kim; Kanjiro Miyata; Kazunori Kataoka

doi:10.1016/j.addr.2016.06.011

Recent progress in development of siRNA delivery vehicles for cancer therapy

Adv Drug Deliv Rev. 2016 Sep 1:104:61-77. doi: 10.1016/j.addr.2016.06.011. Epub 2016 Jun 25.

Authors

Hyun Jin Kim¹, Ahram Kim², Kanjiro Miyata¹, Kazunori Kataoka³

Affiliations

¹ Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
² Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
³ Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan; Innovation Center of NanoMedicine, Institute of Industry Promotion-Kawasaki, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan. Electronic address: kataoka@bmw.t.u-tokyo.ac.jp.

PMID: 27352638
DOI: 10.1016/j.addr.2016.06.011

Abstract

Recent progress in RNA biology has broadened the scope of therapeutic targets of RNA drugs for cancer therapy. However, RNA drugs, typically small interfering RNAs (siRNAs), are rapidly degraded by RNases and filtrated in the kidney, thereby requiring a delivery vehicle for efficient transport to the target cells. To date, various delivery formulations have been developed from cationic lipids, polymers, and/or inorganic nanoparticles for systemic delivery of siRNA to solid tumors. This review describes the current status of clinical trials related to siRNA-based cancer therapy, as well as the remaining issues that need to be overcome to establish a successful therapy. It, then introduces various promising design strategies of delivery vehicles for stable and targeted siRNA delivery, including the prospects for future design.

Keywords: Cancer therapy; Polyion complex micelle; RNAi; Systemic administration; siRNA delivery.

Publication types

Review

MeSH terms

Animals
Drug Delivery Systems*
Humans
Nanoparticles*
Neoplasms / genetics
Neoplasms / therapy*
Polymers
RNA, Small Interfering / administration & dosage*
RNA, Small Interfering / therapeutic use

Substances

Polymers
RNA, Small Interfering